The STASH trial (Short for "Steroid Tapering in Severe Alcohol-associated Hepatitis") was a multicenter, open-label randomized clinical trial aimed at evaluating the efficacy and safety of a tapered prednisolone regimen compared to the standard fixed-dose regimen in patients with severe alcohol-associated hepatitis (AAH). The trial was conducted to address concerns about the high risk of infections associated with corticosteroid treatment in AAH patients, while still preserving its therapeutic benefits. Background: Severe AAH is a life-threatening condition characterized by liver inflammation due to excessive alcohol consumption. Corticosteroids, such as prednisolone, are the standard treatment for severe AAH because they reduce liver inflammation and improve short-term survival. However, corticosteroids suppress the immune system, leading to a high risk of secondary infections, which can worsen patient outcomes. Clinical guidelines recommend a fixed daily dose of 40 mg prednisolone for 28 days, but there has been ongoing debate about whether a tapering regimen could reduce infection risks while maintaining efficacy. Study Design: Study Period: March 2023 to August 2024. Participants: 254 adults diagnosed with severe AAH. Intervention Groups: Fixed-dose group: Participants received 40 mg/day of prednisolone for 28 days (standard regimen). Tapered-dose group: Participants received a four-week tapering regimen of prednisolone (gradual dose reduction over 28 days). Primary Endpoint: Incidence of infections by day 90, assessed using standardized criteria. Secondary Endpoints: Mortality at day 90, transplant-free survival, liver function improvement (measured by MELD score), rates of acute kidney injury (AKI), and overall adverse events. Key Findings: Infection Risk: Tapered-dose group had significantly fewer infections by day 90 compared to the fixed-dose group (19.7% vs. 33.1%). Microbiologically confirmed infections were also reduced in the tapered-dose group. The most common infections were lung infections, followed by urinary and peritoneal infections. Mortality and Survival: Despite the reduction in infection rates, there was no significant difference in day-90 mortality or transplant-free survival between the two groups. Liver Function and AKI: Both groups showed similar improvements in liver function (MELD score) and comparable rates of acute kidney injury. Adverse Events: Overall adverse events and hospitalizations were more frequent in the fixed-dose group, suggesting a safety advantage with the tapering regimen. Conclusion: The STASH trial demonstrated that a tapered prednisolone regimen significantly reduces the risk of infections in patients with severe AAH compared to the standard fixed-dose regimen. Importantly, this reduction in infection risk was achieved without compromising short-term survival or liver function improvement. These findings suggest that tapering corticosteroids is a safer and more effective strategy for managing severe AAH, addressing the long-standing challenge of balancing immunosuppression with infection risk. Implications: The results of the STASH trial could lead to a revision of current clinical guidelines for the treatment of severe AAH, favoring a tapered prednisolone regimen over the fixed-dose approach. This approach may improve patient safety and outcomes by minimizing secondary infections, which are a major cause of morbidity and mortality in this population.

Redefining care for Primary Sclerosing Cholangitis (PSC) requires a comprehensive, patient-centered approach that integrates modern strategies for symptom management, disease progression monitoring, and quality-of-life improvements. PSC is a chronic liver disease with significant unmet needs, including severe symptoms, high cancer risks, and limited therapeutic options. Below is a detailed breakdown of how PSC care is being redefined: Symptom Management: Addressing Quality-of-Life Concerns Pruritus (Itching): Pruritus is one of the most common and debilitating symptoms of PSC, affecting about 50% of patients, with 30% experiencing moderate-to-severe itching. Despite the widespread use of treatments like bile acid sequestrants (36%), hydroxyzine (23%), rifampicin (17%), and naltrexone (14%), many of these therapies have limited efficacy. Call for Better Therapies: There is an urgent need for safe, effective, and long-term antipruritic medications. The FITCH trial demonstrated promising results with bezafibrate, which improved pruritus by at least 50% in 41% of patients compared to 11% in the placebo group. Patient Priorities: Symptom relief, particularly pruritus, is a top motivator for patients joining drug trials, highlighting the importance of addressing quality-of-life symptoms in care strategies. Structured Surveillance and Monitoring Scheduled ERCP Follow-Up: Regularly scheduled ERCP (endoscopic retrograde cholangiopancreatography) interventions have been shown to improve long-term transplant-free survival and reduce infections compared to on-demand procedures. The low complication rate (4%) ensures safety when the procedure is performed in a structured, protocolized manner. Routine MRCP Surveillance: Magnetic resonance cholangiopancreatography (MRCP) allows earlier detection of dominant strictures and cholangiocarcinoma, which leads to better survival outcomes. Routine MRCP reduces the risk of death by 73.8% compared to symptom-triggered imaging (HR 0.9, p < 0.001). This proactive approach identifies disease progression earlier and enables timely interventions. Stricture-Driven Management: The benefits of MRCP surveillance come from proactive management of biliary strictures rather than relying solely on late detection of hepatic malignancies. Patient Involvement in Research Engagement Gap: While 61% of patients are willing to participate in clinical trials, only 26% have been asked, highlighting a significant gap in patient engagement and recruitment. Patient Motivation: Pruritus relief is the top motivator for PSC patients joining drug trials, emphasizing the need for trials focused on quality-of-life improvements and symptom control. Future Directions: Greater inclusion of patient-reported outcome measures in research and therapeutic development is essential for personalized care. Cancer Screening and Risk Management High Cancer Risk: PSC remains a progressive disease with a high risk for hepatobiliary and colorectal cancers. Surveillance strategies like MRCP and ERCP are critical for early detection of cholangiocarcinoma and dominant strictures. Earlier Detection Advantage: Routine imaging allows for timely interventions that improve survival outcomes. Modern Therapeutic Development Personalized Care: Future PSC care will emphasize personalized, high-quality ambulatory hepatology care tailored to individual patient needs. ABCDE Model: A stepwise PSC care strategy includes: Awareness: Educating patients about PSC and its risks. Bile ducts: Monitoring and managing strictures and infections. Cancer: Screening for hepatobiliary and colorectal cancers. Disability: Addressing quality-of-life symptoms like pruritus and fatigue. Explore trials: Encouraging participation in clinical trials to advance treatment options. Improved Disease Management Long-Term ERCP Follow-Up: Regular ERCP interventions help identify disease progression earlier and reduce recurrent cholangitis episodes, improving transplant-free survival. State-of-the-Art Review Findings: Modern care strategies focus on halting disease progression and improving life quality through symptom control, structured surveillance, and personalized treatment approaches. Conclusion: Redefining PSC Care Redefining PSC care involves combining early symptom-focused interventions, structured surveillance (MRCP/ERCP), and personalized treatment approaches. This integrated strategy targets both halting disease progression and improving patient quality of life. The urgent need for effective antipruritic therapies, better patient engagement in research, and proactive cancer screening further underscores the importance of modernizing PSC care. By addressing unmet needs and leveraging advancements in monitoring and therapeutic development, PSC care can significantly improve long-term outcomes and provide patients with a better quality of life.

Hepatitis

Q: Up to One in Four Patients With PBC May Already Have Cirrhosis at Diagnosis: Advance GastroHep | August 2026

Introduction: Primary biliary cholangitis (PBC) is a progressive cholestatic liver disease in which early diagnosis and treatment can prevent progression to cirrhosis. However, many patients remain asymptomatic and undiagnosed for years. This large U.S. Veterans Affairs study evaluated the real-world prevalence of PBC and, importantly, how frequently patients already had cirrhosis when PBC was first diagnosed. Why was this study needed? Up to half of individuals with PBC may remain undiagnosed. Many patients are asymptomatic, contributing to delayed recognition. The true prevalence of PBC in the United States remains uncertain. Delayed diagnosis may allow preventable progression to advanced liver disease. Results: Among >5.1 million U.S. veterans, estimated PBC prevalence ranged from 19.5–76.2 per 100,000, depending on diagnostic criteria. PBC was more prevalent among women, individuals ≥60 years, and Hispanic and Asian/Pacific Islander populations. Most importantly, 11–26% of patients already had cirrhosis at PBC diagnosis, with advanced disease generally more frequent in men. Clinical Impact: The finding that up to one-quarter of patients may have cirrhosis when PBC is first recognized highlights a major diagnostic gap. Greater awareness of unexplained cholestatic liver tests and timely antimitochondrial antibody (AMA) testing could facilitate earlier diagnosis and treatment before irreversible liver damage develops. Bottom Line: PBC remains substantially under-recognized, with up to one in four patients already having cirrhosis at diagnosis. Earlier investigation of persistent cholestatic liver abnormalities and appropriate AMA testing may identify PBC before progression to advanced liver disease.

Q: A Steroid-Sparing Breakthrough(Obexelimab) for IgG4-Related Disease: NEJM | June 2026

Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern. The INDIGO trial evaluated obexelimab, a novel B-cell modulator, as a steroid-sparing therapy. Why was this study needed? Relapse is common after glucocorticoid withdrawal in IgG4-RD. Long-term corticosteroid therapy is associated with substantial toxicity. Effective steroid-sparing therapies are limited. Conventional B-cell depletion has safety and relapse concerns. Novel targeted therapies are needed to maintain durable remission. Results: Obexelimab significantly reduced disease flares, prolonging flare-free survival compared with placebo over 52 weeks. Patients receiving obexelimab achieved higher complete remission rates while requiring substantially less rescue glucocorticoid therapy. Obexelimab was well tolerated, with fewer serious adverse events than placebo despite mild increases in arthralgia, hypersensitivity, and diarrhea. Clinical Impact: The INDIGO trial establishes obexelimab as the first phase III biologic to demonstrate robust steroid-sparing efficacy in IgG4-related disease. Unlike conventional B-cell-depleting therapies, obexelimab modulates B-cell activity without depleting B cells, offering a novel therapeutic approach with the potential to reduce long-term corticosteroid exposure. Bottom Line: Obexelimab represents a major therapeutic advance for IgG4-related disease. It significantly reduces disease flares, increases sustained remission, and minimizes glucocorticoid exposure, making it a promising new targeted treatment for this chronic multisystem disorder.

Q: ML Predicts Response to TPE in Pediatric ALF: JCEH | July 2026

Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent liver transplantation. This study developed machine learning (ML) models to predict response to TPE and support real-time clinical decision-making. Why was this study needed? TPE alters conventional prognostic markers, complicating transplant decisions. Reliable early predictors of TPE response are lacking. Delayed recognition of treatment failure may adversely affect survival. Machine learning may improve individualized risk prediction. A real-time clinical decision support tool could enhance patient management. Results: Machine learning models accurately predicted response to TPE, with the best performance 12–18 hours after the first TPE session, allowing early identification of responders and non-responders. Logistic Regression, Support Vector Machine (SVM), and XGBoost showed the highest predictive performance, consistently outperforming other ML models. These validated models were integrated into a web-based clinical decision support tool, enabling real-time prediction of TPE response to assist liver transplant decision-making. Clinical Impact: This study demonstrates that artificial intelligence can support critical decision-making in pediatric acute liver failure by identifying children unlikely to respond to TPE at an early stage. Such tools may help optimize transplant timing while avoiding unnecessary delays in life-saving treatment. Bottom Line: Machine learning can accurately predict response to therapeutic plasma exchange in pediatric acute liver failure. A simple web-based prediction tool may assist clinicians in determining which children are likely to recover with TPE and which may require urgent liver transplantation.

Q: Alcohol Intake and Health Study: J of Studies on Alcohol and Drugs | July 2026

Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related diseases and injuries. Why was this study needed? Current drinking recommendations remain controversial because many previous studies suggested a protective effect of moderate alcohol intake. Updated evidence was needed to quantify the lifetime risks associated with different drinking levels and patterns. What did the study show? No overall protective health benefit was observed, even at low levels of alcohol consumption. Alcohol-related mortality and morbidity increased progressively with increasing weekly alcohol intake. Lifetime alcohol-attributable mortality exceeded 1 in 1,000 at approximately 7 drinks per week. At around 8–9 drinks per week, the lifetime risk increased to more than 1 in 100. Men consuming 14 drinks per week had an estimated 1 in 25 (4%) lifetime risk of dying from an alcohol-attributable cause. Drinking more than one drink per occasion further increased the risks of breast cancer, cardiovascular disease, and injuries. The findings support limiting alcohol intake to no more than one standard drink per day for both men and women. Clinical Impact: These findings challenge the long-held perception that moderate alcohol consumption is beneficial. Clinicians should counsel patients that alcohol-related health risks begin at relatively low levels of intake and increase further with higher weekly consumption and binge drinking patterns. Take-Home Message: This large U.S. study found no net health benefit from low-to-moderate alcohol consumption. Alcohol-related health risks rise progressively with increasing intake, supporting a simple public health message: less alcohol is better, and if consumed, intake should ideally be limited to one drink or less per day.

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated August 1, 2026

Overview

Evidence-based insights. Better liver health

Liver Biopsy Reveals Distinct Patterns of Checkpoint Inhibitor–Related Liver Injury: Hepatology Communications | August 2026

Introduction: Immune checkpoint inhibitors (ICIs) can cause immune-mediated liver injury, ranging from hepatocellular hepatitis to cholestatic or mixed patterns. Although liver biopsy may clarify the diagnosis and severity, its optimal timing and clinical value remain...

Up to One in Four Patients With PBC May Already Have Cirrhosis at Diagnosis: Advance GastroHep | August 2026

Introduction: Primary biliary cholangitis (PBC) is a progressive cholestatic liver disease in which early diagnosis and treatment can prevent progression to cirrhosis. However, many patients remain asymptomatic and undiagnosed for years. This large U.S. Veterans...

Pruritus in Primary Sclerosing Cholangitis: Hepatology | August 2026

Introduction: Pruritus is one of the most troublesome symptoms experienced by patients with primary sclerosing cholangitis (PSC), yet its natural history has been poorly understood. As disease-modifying therapies remain unavailable, improving symptom control has become...

Iptacopan Preserves Kidney Function in IgA Nephropathy: NEJM | August 2026

Introduction: IgA nephropathy is a progressive immune-mediated kidney disease in which alternative complement pathway activation contributes to glomerular inflammation and renal injury. Iptacopan is an oral selective complement factor B inhibitor that targets this pathway....

A Steroid-Sparing Breakthrough(Obexelimab) for IgG4-Related Disease: NEJM | June 2026

Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern....

HBV Reactivation During Immunosuppressive Therapy: Alimentary Pharmacology & Therapeutics | July 2026

Introduction: Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that...

Advancing Liver Health in a Shifting Global Landscape: Nat Re Gastro & Hepatol | July 2026

Introduction: Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent...

ML Predicts Response to TPE in Pediatric ALF: JCEH | July 2026

Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent...

Alcohol Intake and Health Study: J of Studies on Alcohol and Drugs | July 2026

Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related...

Genetic Testing in Adult Cholestatic Liver Disease: Gut | June 2026

Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus,...

Genetic Testing in Adult Cholestatic Liver Disease: Gut | July 2026

ELF and Liver Disease: Gut | May 2026

Introduction: Early detection of advanced fibrosis in steatotic liver disease remains a major clinical challenge, particularly in individuals with type 2 diabetes and hazardous alcohol use. This real-world UK study evaluated the role of the...

The Liver as a Target for Healthy Aging : Ageing Res Rev | June 2026

Introduction: Aging is a complex biological process that affects multiple organs and progressively increases vulnerability to chronic diseases. Among these organs, the liver occupies a central role in maintaining systemic homeostasis through regulation of glucose...

Bezafibrate Shows Meaningful Long-Term Benefit in PBC : J Hepatol | June 2026

Introduction: Ursodeoxycholic acid (UDCA) remains the first-line treatment for primary biliary cholangitis (PBC), yet a substantial proportion of patients fail to achieve complete biochemical response. Persistent elevation of alkaline phosphatase (ALP) after UDCA therapy is...

MELD Exceptions in PSC Under Scrutiny : Liver Transpl | June 2026

Introduction: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that frequently progresses to liver failure, recurrent bacterial cholangitis, and the need for liver transplantation. Because the Model for End-Stage Liver Disease (MELD) score...

Precision HBV Care Moves Toward Functional Cure : Frontline Gastroenterology | May 2026

Introduction Chronic Hepatitis B remains a leading global cause of cirrhosis and Hepatocellular Carcinoma despite the availability of potent antiviral therapy. However, management strategies are rapidly evolving from simple viral suppression toward precision, biomarker-driven care...

PLEX Shows Limited Overall Benefit in HAV-ALF : Indian J Gastroenterol | May 2026

Introduction Acute Liver Failure caused by Hepatitis A remains an important cause of mortality in young adults in developing countries. Although Therapeutic Plasma Exchange has shown benefit in acute liver failure overall, disease-specific evidence in...

Bepirovirsen Achieves Functional Cure in Chronic Hepatitis B: NEJM | May 2026

Bepirovirsen is an antisense oligonucleotide that targets HBV transcripts, aiming to reduce viral proteins and achieve a functional cure rather than lifelong viral suppression. In two large Phase 3 trials (B-Well 1 and B-Well 2),...

High Placebo Response Rates Continue to Challenge MASH Drug Trials : Clinical Gastroenterology and Hepatology | May 2026

Introduction Metabolic dysfunction–associated steatohepatitis (MASH) has become a major global liver disease burden and a central focus of therapeutic development. Despite intense pharmaceutical activity and numerous late-phase clinical trials, demonstrating meaningful histologic improvement remains challenging,...

Hepatitis B Vaccination: A Success Story - Gastroenterology | March 26

Introduction Hepatitis B virus (HBV) infection remains a major global health threat, with an estimated 254 million people living with chronic infection and more than 1.1 million deaths annually from cirrhosis and hepatocellular carcinoma (HCC)....

Prognostic value of LSM in PBC- AJG Feb.26

Risk stratification in primary biliary cholangitis (PBC) traditionally relies on biochemical response to ursodeoxycholic acid, but liver stiffness measurement (LSM) is increasingly used to assess fibrosis and portal hypertension. In everyday practice, clinicians often encounter...

How Alcohol Acts as a ‘Second Hit’ in HBV-Driven Liver Cancer- AJG Feb.26

Introduction Hepatocellular carcinoma (HCC) commonly arises from chronic liver injury due to hepatitis B virus (HBV), alcohol use, metabolic dysfunction, or combinations of these factors. While each risk factor independently promotes carcinogenesis, how alcohol synergises...

EUS-guided liver biopsy – a novel technique (GIE, Jan-2026)

Indications of EUS-Guided Liver Biopsy EUS-guided liver biopsy (EUS-LB) is increasingly utilized as a minimally invasive technique for obtaining liver tissue samples. Common indications for EUS-LB include: Evaluation of unexplained liver abnormalities, such as elevated...

HBV Genotype and Biomarkers Predict Severe Flares After NA Cessation

The study highlights the significant role of HBV genotype and end-of-treatment (EOT) biomarkers in predicting severe virologic relapses (SVRel) and severe biochemical flares (SBF) after nucleos(t)ide analogue (NA) cessation in patients with chronic hepatitis B...

The hepatitis B vaccine—the first anti-cancer vaccine (Lancet Gastro Hepato 2026)

The hepatitis B vaccine, often hailed as the first anti-cancer vaccine, represents a groundbreaking achievement in global public health. Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC), a deadly...

Rat Hepatitis E - J of Hepatology-Jan.26

Rat Hepatitis E (rHEV), also known as Rocahepevirus ratti, is an emerging zoonotic pathogen that has garnered significant attention in recent years due to its potential to infect humans and cause clinical disease. It was...

HBsAg, HBeAg and HCC prediction

HBsAg (Hepatitis B surface antigen) and HBeAg (Hepatitis B e antigen) are important biomarkers in understanding the progression and risk factors of chronic hepatitis B virus (HBV) infection, particularly in relation to hepatocellular carcinoma (HCC)...

Large-Scale Profiling of HBsAg Levels in Chronic Hepatitis B for Functional Cure Development

The large-scale profiling of hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B (CHB) is a critical area of research aimed at advancing the development of therapies for achieving a functional cure....

STASH Trial

The STASH trial (Short for "Steroid Tapering in Severe Alcohol-associated Hepatitis") was a multicenter, open-label randomized clinical trial aimed at evaluating the efficacy and safety of a tapered prednisolone regimen compared to the standard fixed-dose...

Zetomipzomib and the PORTOLA Trial

Zetomipzomib and the PORTOLA Trial represent a significant advancement in the treatment of autoimmune hepatitis (AIH), particularly for patients who are inadequately controlled on standard therapies like steroids and azathioprine. Below is a detailed explanation...

Redefining PSC Care

Redefining care for Primary Sclerosing Cholangitis (PSC) requires a comprehensive, patient-centered approach that integrates modern strategies for symptom management, disease progression monitoring, and quality-of-life improvements. PSC is a chronic liver disease with significant unmet needs,...

Treatment of Chronic Hepatitis B - AASLD/IDSA Guideline 2025

As of my knowledge cutoff in October 2023, the most recent guidelines for the treatment of chronic hepatitis B (CHB) were published by the American Association for the Study of Liver Diseases (AASLD) and the...

Secondary Iron Overload and the Liver

Secondary iron overload is more common than hereditary hemochromatosis and arises from conditions such as transfusions, ineffective erythropoiesis, and chronic liver diseases. Iron absorption is regulated by hepcidin, which suppresses ferroportin when iron levels are...

Cardiac Syndromes in Liver Disease

Cardiac syndromes in liver disease encompass a spectrum of complex interactions between the heart and liver, with both organs mutually influencing each other. These syndromes include congestive hepatopathy (CH), cardiogenic liver injury (CLI), cirrhotic cardiomyopathy...

Overview

Liver Biopsy Reveals Distinct Patterns of Checkpoint Inhibitor–Related Liver Injury: Hepatology Communications | August 2026

Up to One in Four Patients With PBC May Already Have Cirrhosis at Diagnosis: Advance GastroHep | August 2026

Pruritus in Primary Sclerosing Cholangitis: Hepatology | August 2026

Iptacopan Preserves Kidney Function in IgA Nephropathy: NEJM | August 2026

A Steroid-Sparing Breakthrough(Obexelimab) for IgG4-Related Disease: NEJM | June 2026

HBV Reactivation During Immunosuppressive Therapy: Alimentary Pharmacology & Therapeutics | July 2026

Advancing Liver Health in a Shifting Global Landscape: Nat Re Gastro & Hepatol | July 2026

ML Predicts Response to TPE in Pediatric ALF: JCEH | July 2026

Alcohol Intake and Health Study: J of Studies on Alcohol and Drugs | July 2026

Genetic Testing in Adult Cholestatic Liver Disease: Gut | June 2026

Genetic Testing in Adult Cholestatic Liver Disease: Gut | July 2026

ELF and Liver Disease: Gut | May 2026

The Liver as a Target for Healthy Aging : Ageing Res Rev | June 2026

Bezafibrate Shows Meaningful Long-Term Benefit in PBC : J Hepatol | June 2026

MELD Exceptions in PSC Under Scrutiny : Liver Transpl | June 2026

Precision HBV Care Moves Toward Functional Cure : Frontline Gastroenterology | May 2026

PLEX Shows Limited Overall Benefit in HAV-ALF : Indian J Gastroenterol | May 2026

Bepirovirsen Achieves Functional Cure in Chronic Hepatitis B: NEJM | May 2026

High Placebo Response Rates Continue to Challenge MASH Drug Trials : Clinical Gastroenterology and Hepatology | May 2026

Hepatitis B Vaccination: A Success Story - Gastroenterology | March 26

Prognostic value of LSM in PBC- AJG Feb.26

How Alcohol Acts as a ‘Second Hit’ in HBV-Driven Liver Cancer- AJG Feb.26

EUS-guided liver biopsy – a novel technique (GIE, Jan-2026)

HBV Genotype and Biomarkers Predict Severe Flares After NA Cessation

The hepatitis B vaccine—the first anti-cancer vaccine (Lancet Gastro Hepato 2026)

Rat Hepatitis E - J of Hepatology-Jan.26

HBsAg, HBeAg and HCC prediction

Large-Scale Profiling of HBsAg Levels in Chronic Hepatitis B for Functional Cure Development

STASH Trial

Zetomipzomib and the PORTOLA Trial

Redefining PSC Care

Treatment of Chronic Hepatitis B - AASLD/IDSA Guideline 2025

Secondary Iron Overload and the Liver

Cardiac Syndromes in Liver Disease

More topics

Small and Large Bowel

Exam Corner

Artificial Intelligence

Cirrhosis Liver

Liver Transplantation

Fatty Liver Disease

Endoscopy

Basic Sciences

HCC

IBD

Oncology

Gallbladder and Pancreas

Upper GI Tract

GI Surgery

For You

Core Tools

Explore

Overview

Liver Biopsy Reveals Distinct Patterns of Checkpoint Inhibitor–Related Liver Injury: Hepatology Communications | August 2026

Up to One in Four Patients With PBC May Already Have Cirrhosis at Diagnosis: Advance GastroHep | August 2026

Pruritus in Primary Sclerosing Cholangitis: Hepatology | August 2026

Iptacopan Preserves Kidney Function in IgA Nephropathy: NEJM | August 2026

A Steroid-Sparing Breakthrough(Obexelimab) for IgG4-Related Disease: NEJM | June 2026

HBV Reactivation During Immunosuppressive Therapy: Alimentary Pharmacology & Therapeutics | July 2026

Advancing Liver Health in a Shifting Global Landscape: Nat Re Gastro & Hepatol | July 2026

ML Predicts Response to TPE in Pediatric ALF: JCEH | July 2026

Alcohol Intake and Health Study: J of Studies on Alcohol and Drugs | July 2026

Genetic Testing in Adult Cholestatic Liver Disease: Gut | June 2026

Genetic Testing in Adult Cholestatic Liver Disease: Gut | July 2026

ELF and Liver Disease: Gut | May 2026

The Liver as a Target for Healthy Aging : Ageing Res Rev | June 2026

Bezafibrate Shows Meaningful Long-Term Benefit in PBC : J Hepatol | June 2026

MELD Exceptions in PSC Under Scrutiny : Liver Transpl | June 2026

Precision HBV Care Moves Toward Functional Cure : Frontline Gastroenterology | May 2026

PLEX Shows Limited Overall Benefit in HAV-ALF : Indian J Gastroenterol | May 2026

Bepirovirsen Achieves Functional Cure in Chronic Hepatitis B: NEJM | May 2026

High Placebo Response Rates Continue to Challenge MASH Drug Trials : Clinical Gastroenterology and Hepatology | May 2026

Hepatitis B Vaccination: A Success Story - Gastroenterology | March 26

Prognostic value of LSM in PBC- AJG Feb.26

How Alcohol Acts as a ‘Second Hit’ in HBV-Driven Liver Cancer- AJG Feb.26

EUS-guided liver biopsy – a novel technique (GIE, Jan-2026)

HBV Genotype and Biomarkers Predict Severe Flares After NA Cessation

The hepatitis B vaccine—the first anti-cancer vaccine (Lancet Gastro Hepato 2026)

Rat Hepatitis E - J of Hepatology-Jan.26